![]() Today the Company filed its financial statements later than anticipated due to unforeseen delays with its audit. I want to thank our patients, employees, partners and investors, and look forward to rapidly expanding our model to meet demand for psychedelic medicine and other innovative mental health treatments.” Our unique business model serving both patients and drug developers is growing significantly, reflected by an expanded clinic network, new clinical programs and research partnerships, and strong additions to our staff and leadership. Yaron Conforti, CEO and Director, commented: “Novamind had strong financial and operating performance in its first year as a public company. All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified. (CSE:NM | OTCQB:NVMDF | FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, reported its audited financial results for the twelve months ended J(“FY2021”). TORONTO, ON / ACCESSWIRE / Novem/ Novamind Inc. ![]() Granted DEA Schedule 1 licenses for psilocybin research. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |